Pyxis Oncology, Inc. (PYXS)

NASDAQ: PYXS · IEX Real-Time Price · USD
3.00
0.00 (0.00%)
Aug 17, 2022 4:30 PM EDT - Market closed
0.00%
Market Cap 98.50M
Revenue (ttm) n/a
Net Income (ttm) -87.95M
Shares Out 32.83M
EPS (ttm) -4.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 29,512
Open 2.94
Previous Close 3.00
Day's Range 2.87 - 3.10
52-Week Range 1.96 - 19.00
Beta n/a
Analysts Buy
Price Target 13.77 (+359.0%)
Earnings Date Aug 12, 2022

About PYXS

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates ... [Read more...]

Industry Biotechnology
IPO Date Oct 1, 2021
Employees 64
Stock Exchange NASDAQ
Ticker Symbol PYXS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for PYXS stock is "Buy." The 12-month stock price forecast is 13.77, which is an increase of 359.00% from the latest price.

Price Target
$13.77
(359.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update

• Prioritized pipeline to focus on most advanced programs while maintaining financial flexibility to pursue business development opportunities

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, reported o...

Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference

CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, today anno...

Pyxis Oncology Announces Presentations at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat can...

Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat can...

Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat c...

Pyxis Oncology Announces Leadership Changes

- Ronald Herbst, Ph.D., stepping down as Chief Scientific Officer -

Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022...

- Data highlight PYX-106's differentiated activity profile and antitumor activity in an in vivo mouse model -

Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology

- Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody - Biosion earns a $10 million upfron...

Pyxis Oncology Provides Corporate and Financial Update

Announces Expansion of Novel Immuno-Oncology Therapeutic Portfolio with Addition of Anti-Siglec-15 In-licensed from Biosion (PYX-106)

Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022

CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset, multi-modality company focused on developing next-generation therapeutics for difficult to treat ...

Pyxis to be Added to Russell 2000® Index

CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers,...

Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer

Industry veteran brings expertise in corporate strategy and business development to Pyxis team Industry veteran brings expertise in corporate strategy and business development to Pyxis team

Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief Business Officer

WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief Business Officer

Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update

CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers,...

Pyxis Oncology to Present at the Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), today announced that management will present at and host one-on-one investor meetings during the virtual portion ...

Pyxis Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficu...